Apimeds Pharmaceuticals US (APUS) Cash from Financing Activities (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Cash from Financing Activities came in at $8.5 million in Q4 2025, up 11001.54% on a YoY basis from N/an in Q4 2024, and down 28.39% quarter-over-quarter from $11.9 million in Q2 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Cash from Financing Activities (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Cash from Financing Activities for 2 consecutive years, with $8.5 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 11001.54% year-over-year to $8.5 million; the trailing twelve-month figure through Dec 2025 stood at $20.6 million (changed N/A YoY), and the FY2025 full-year result was $20.6 million, up 6215.26% from the prior year.
- Cash from Financing Activities declined to $8.5 million in Q4 2025 per APUS's latest filing, from $11.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $11.9 million in Q2 2025 and bottomed at $76500.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -181.51 Mn |
| 10 | Apimeds Pharmaceuticals US | 3.79 Mn | 3.79 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 8.49 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Mar 31, 2025 | 267,200.00 |
| Dec 31, 2024 | 76,500.00 |
| Sep 30, 2024 | 150,000.00 |